Note: Descriptions are shown in the official language in which they were submitted.
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
1
PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION TO NAILS
Description
BACKGROUND OF THE INVENTION
The present invention is in the field of pharmacotherapy. More specifically,
it
relates to the treatment of diseases and conditions affecting the nails of
humans and
other mammals.
While many cutaneous disorders affect the skin itself, there also exist
diseases
and conditions which relate to the skin appendages, in particular to the
nails. These
are often difficult to treat due to the thick and dense nail plate largely
composed of
keratin and its poor uptake of therapeutic agents.
Nails are hardenings of the horny zone of the epidermis. They appear as sheet-
like appendages covering the skin on the dorsal side of the terminal phalanges
of
fingers and toes. The horny zone of the nail is composed of hard alpha-keratin
and
has a distal, exposed part, or body, and a proximal, hidden portion, or root.
The root is
covered by a distal prolongation of the stratum corneum of the skin. This
narrow fold
is composed of soft-keratin and is termed the eponychium. Distal to the
eponychium
is the "half-moon," or lunula, a part of the horny zone that is opaque to the
underlying
capillaries.
Deep to the distal or free border of the nail, the horny zone of the fingertip
is
thickened and is frequently termed the hyponychium. The horny zone of the nail
is
attached to the underlying nail bed. The matrix, or proximal part of the bed,
produces
hard-keratin. Further distally, however, the bed may also generate nail
substance.
Moreover, the most superficial layer of the nail may be produced by the
epithelium
immediately dorsal to the root and proximal to the eponychium. The growth of
the
nail is affected by nutrition, hormones, and disease. Nail growth involves
considerable
protein synthesis, as a result of which nonspecific changes occur in the nails
in
response to various local and systemic disturbances.
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
2
Nails develop in the foetus as epidermal thickenings that undercut the skin to
form folds from which the horny substance of the nail grows distally. In adult
humans, it takes about 6 months for a fingernail to form, which corresponds to
a
growth rate of approx. 2-3 mm per month. Toenails tend to grow more slowly
than
fingernails.
Nails are about two magnitudes thicker than the stratum corneum of the skin.
Hard alpha-keratin, the major constituent of the horny zone, is a fibrous
structural
protein characterised by a high content of cysteine which readily forms
thermostable
crosslinks via sulphide bridges. The water content of nails is rather low, and
typically
ranges from about 10 to 30 %. Generally speaking, nails are very resistant to
the
permeation of molecules such as drug substances.
The main function of nails is to protect the sensitive tips of fingers and
toes. In
addition, fingernails serve in scratching. Toenails are also important for
balance.
One of the most common diseases affecting the nail apparatus is fungal
infection, also referred to as onychomycosis, a condition affecting about 20%
of the
adult population in the USA. The incidence is increasing worldwide. In fact,
about
30% of all superficial fungal infections affect the nail. Infection may be due
to
dermatophyte (ringworm, tinea unguium), yeast, or other non-dermatophyte
(mould)
species. In paronychia, chronic infection of the nail fold is most often
caused by
Candida species, but bacterial infection with Gram negative species such as
Pseudomonas may coexist. Acute paronychia (whitlow) due to staphylococcal
infection may also occur, and the presence of these bacterial infections will
influence
management. Invasion of the nail plate by Candida species may occur in the
presence
of paronychia, immune deficiency states (including chronic mucocutaneous
candidiasis), Raynaud's disease, or endocrine disorders.
Another common condition is nail psoriasis, one of the possible manifestations
of psoriasis, which produces a variety of changes in the appearance of finger
and toe
nails. These changes include discolouring under the nail plate, pitting of the
nails,
lines going across the nails, thickening of the skin under the nail, and the
loosening
(onycholysis) and crumbling of the nail.
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
3
Most people who have psoriasis of the nails also have skin psoriasis
(cutaneous
psoriasis). Only 5% of people with psoriasis of the nails do not have skin
psoriasis. In
people who have skin psoriasis, 10%-55% have psoriasis of the nails (also
called
psoriatic nail disease). About 10%-20% of people who have skin psoriasis also
have
psoriatic arthritis, a specific condition in which people have symptoms of
both
arthritis and psoriasis. Of people with psoriatic arthritis, 53%-86% have
affected
nails, often with pitting.
Another condition of the nail is onychia, which is an inflammation of the nail
folds surrounding tissue of the nail plate with formation of pus and shedding
of the
nail. One of the causes of onychia is a posttraumatic bacterial infection.
Onycholysis refers to a loosening of the exposed portion of the nail from the
nail
bed, usually beginning at the free edge and continuing to the lunula. It may
be related
to numerous possible causes including infections and allergic reactions.
A number of other nail conditions such as onychodystrophy, onychomadesis,
and onychoptosis often represent adverse reactions to drugs, for example
antibiotics
or anticancer agents.
Interestingly, conditions of the nails are rather often treated systemically,
which
itself indicates how difficult it is to achieve a therapeutic drug
concentration in the
nails by local administration. For example, onychomycosis is treated with oral
terbinafine 250 mg daily for 3-6 months, or itraconazole 200 mg daily for 3-6
months.
Even the rather conventional therapy with oral griseofulvin 10mg/kadaily (500
mg
twice daily) for 6-18 months is still being recommended today. In particular
proximal
nail disease or severe nail bed involvement are being considered as
indications for
systemic rather than local treatment.
Some topical preparations of known antifungal agents for treatment of
onychomycosis exist, such as nail lacquers comprising ciclopirox, amorolfine,
or
butenafine. While there is some evidence of efficacy, it is believed that
successful
topical antifungal therapy requires treatment over very long periods, such as
a year
or even more. Some experts recommend the combination of topical and systemic
CA 02834862 2013-10-31
WO 2012/160180
PCT/EP2012/059788
4
treatment for better efficacy. Without adequate treatment and patient
compliance,
the infection will not disappear.
Also for nail psoriasis, the most effective treatment options appear to be
systemic rather than topical. Recent reports suggest that some injectable
biological
medicines such as infliximab and etanercept may be highly effective. However,
these
treatments are associated with substantial risks of adverse effects, and they
are very
expensive.
Topical treatments in their currently available formulations are considered
much less effective. Solutions containing vitamin D derivatives such as
calcipotriol
may be applied twice daily to the nail folds. Topical high-potency
corticosteroid
solutions or ointments are another option. Some experts also recommend 5-
fluorouracil cream applied to the matrix for 6 months to improve pitting and
subungual hyperkeratosis. Antifungal treatment is indicated whenever a
secondary
fungal infection is present, which is very frequent in cases of nail
psoriasis.
There have been various efforts to make topical treatment of nail diseases
more
successful, mostly focussing on an improved permeation of the drug substance
into
the nail matrix. Often, co-treatment with urea cream is recommended in order
to
soften the nail keratin and make it more permeable. While some evidence for an
improved antifungal therapy in combination with urea exists, it still appears
that
systemic therapy with all its risks and adverse effects is considerably more
effective.
Other permeation enhancers have been proposed for enhancing trans-nail
delivery of antifungal agents, such as in US6,042,845, US6,159,977,
US6,224,887 and
US6,391 ,879. Most of the suggested compounds are however not approved for
pharmaceutical products and exhibit unknown health risks.
U.S. Patent No. 5,326,566 describes a composition of a pharmacological agent
in
combination with dibutyl adipate, or a mixture of dibutyl adipate and
isopropyl
myristate, which could enhance the penetration through keratin. However,
substantial problems may arise when the penetration enhancers are incompatible
CA 02834862 2013-10-31
WO 2012/160180
PCT/EP2012/059788
with a particular drug substance, leading to drug instability and degradation
into
potentially harmful degradants.
US 2005/0079210 Al proposes the use of liposomes the epicutaneous
administration of drugs and cosmetically useful agents. However, liposomes are
5 difficult to manufacture cost-effectively and in a reproducible manner.
Other delivery strategies for topical medications require the occlusion of the
nail after administration, which is however perceived as inconvenient by many
patients.
There clearly remains a need for pharmaceutical formulations and vehicles
which allow the effective treatment of nail disorders by topical
administration. It is
therefore an object of the present invention to provide such improved
compositions
which overcome one or more disadvantages of known compositions. In particular,
it
is an object of the invention to provide compositions of topically active drug
substances which can effectively penetrate the dense nail plate and which are
convenient to use. Further objects of the invention will become clear on the
basis of
the description of the invention below, including the examples, and of the
patent
claims.
SUMMARY OF THE INVENTION
The present invention provides a novel pharmaceutical composition for
administration to nails. The composition comprises an effective amount of an
active
ingredient and a semifluorinated alkane (SFA) according to formula RFRH or
RFRHRF, wherein RF is a perfluorinated hydrocarbon segment with 20 or less
carbon
atoms and RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon
atoms.
In a preferred embodiment, the SFA is selected from F4H5, F4H6, F4H8, F6H6 and
F6H8.
It has been surprisingly found by the inventors that SFAs are capable of
delivering active pharmaceutical ingredients effectively into the keratin
matrix of
CA 02834862 2013-10-31
WO 2012/160180
PCT/EP2012/059788
6
finger- and toenails such as to produce therapeutically relevant drug
concentrations
even in deeper regions of the matrix.
The composition may, for example, be in the form of a solution, gel, nail
lacquer,
emulsion, suspension, spray, or patch. It is useful for administering a wide
range of
topical agents useful in various nail diseases and conditions.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the penetration profile of tacrolimus 1,000 min after
administration as an SFA-based formulation to human nails, respectively,
presented
as molar tacrolimus concentration over depth. For further details, see Example
1.
Figure 2 shows the penetration profile of tacrolimus 1,000 min after
administration as an SFA-based formulation to human nails, respectively,
presented
as amount tacrolimus (relative to the administered dose) per layer. For
further
details, see Example 1.
Figure 3 shows the penetration profile of ciclopiroxolamine 1,000 minutes
after
administration as an SFA-based formulation to human nails, respectively,
presented
as amount ciclopiroxolamine (relative to the administered dose) over depth.
For
further details, see Example 2.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides a novel pharmaceutical composition for use as a topical
formulation which is to be administered to nails. The composition comprises an
effective amount of an active ingredient and a semifluorinated alkane
according to
formula RFRH or RFRHRF, wherein RF is a perfluorinated hydrocarbon segment
with
20 or less carbon atoms and RH is a non-fluorinated hydrocarbon segment with 3
to
20 carbon atoms.
The invention is based on the surprising discovery that the semifluorinated
alkanes (SFAs) as defined above are highly suitable carriers for topically
administered drugs and capable of delivering active ingredients deep into the
nail.
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
7
This was particularly unexpected in view of Hardung (Doctoral Thesis, Albert-
Ludwigs-University of Freiburg, Germany, 2008), who investigated the
suitability of
SFAs as carriers for topical medications using e.g. testosterone as a model
drug, and
who came to the conclusion that an SFA such as F6H8 (see below for an
explanation
of the terminology of SFAs) does not affect an improved penetration, nor
interact
with the stratum corneum (whose barrier function also relies on keratin), or
exhibit
any penetration-enhancing effect (p. 103, first full paragraph). However, in
spite of
such discouraging statements in the prior art, the inventors have further
investigated
the impact of SFAs and SFA-based carriers on the delivery of drugs into the
keratin
.. matrix of nails using excised human nails (in contrast to Hardung who
worked with
pig skin as a model), and have now surprisingly found that SFAs are indeed
capable of
enhancing the penetration of drugs into nails, as will be shown in more detail
below.
As used herein, a pharmaceutical composition is any composition comprising an
active ingredient useful for the diagnosis, prevention, management or therapy
of a
.. disease, symptom or health condition and at least one carrier or excipient.
A topical
formulation is a composition which is in a form suitable for topical
administration. In
the present invention, the composition is suitable for administration to a
skin
appendage of a subject, which subject may be a human or an animal. The skin
appendage, such as a finger- or toenail, may be intact or injured, bruised,
damaged or
otherwise affected.
Semifluorinated alkanes are linear or branched alkanes some of whose
hydrogen atoms have been replaced by fluorine. In a preferred embodiment, the
semifluorinated alkanes (SFA's) used in the present invention are composed of
at
least one non-fluorinated hydrocarbon segment and at least one perfluorinated
.. hydrocarbon segment. Particularly useful are SFA's which have one non-
fluorinated
hydrocarbon segment attached to one perfluorinated hydrocarbon segment,
according to the general formula F(CF2),,(CH2),,,H, or two perfluorinated
hydrocarbon
segments separated by one non-fluorinated hydrocarbon segment, according to
the
general formula F(CF2)n(CH2).(CF2)0F.
Another nomenclature which is used herein refers to the above-mentioned
SFA's having two or three segments as RFRH and RFRHRF, respectively, wherein
RF
8
designates a perfluorated hydrocarbon segment, R11 designates a non-
fluorinated
segment. Alternatively, the compounds may be referred to as FnHm and FnHmFo,
respectively, wherein F means a perfluorated hydrocarbon segment, H means a
non-
fluorinated segment, and n, m and o is the number of carbon atoms of the
respective
segment. For example, F3H3 is used for perfluoropropylpropane. Moreover, this
type
of nomenclature is usually used for compounds having linear segments.
Therefore,
unless otherwise indicated, it should be assumed that F3H3 means 1-
perfluoropropylpropane, rather than 2-perfluoropropylpropane, 1-
perfluoroisopropylpropane or 2-perfluoroisopropylpropane.
Preferably, the semifluorinated alkanes according to the general formulas
F(CF2)n(CH2)11,H and F(CF2),,(CH2)m(CF2)0F have segment sizes ranging from 3
to 20
carbon atoms, i.e. n, m and o are independently selected in the range from 3
to 20.
SFAs which are useful in the context of the present invention are also
described in EP-
A 965 334, EP-A 965329 and EP-A 2110126
In a further embodiment, the semifluorinated alkane is a compound according
to the formula RFRH, whose segments RF and R11 are linear and each - but
independently from one another - have from 3 to 20 carbon atoms. In another
particular embodiment, the perfluorinated segment is linear and comprises from
4 to
12 carbon atoms, and/or the non-fluorinated segment is linear and comprises
from 4
to 8 carbon atoms. Preferred SFA's include in particular the compounds F4H5,
F4H6,
F4H8, F6H4, F61-I6, F6H8, and F6H10. Presently most preferred for carrying out
the
invention are F4H5, F4H6, F4H8, F6H6 and F6H8.
Optionally, the composition may comprise more than one SFA. It may be useful
to combine SFA's, for example, in order to achieve a particular target
property such as
a certain density, viscosity, or solubilising capacity for a particular active
ingredient.
If a mixture of SFA's is used, it is furthermore preferred that the mixture
comprises at
least one of F4H5, F4116, F4H8, F6H4, F6H6, F6H8, and F6H10, and in particular
one
of F41-IS, F4H6, F4H8, F6H6 and F6H8. In another embodiment, the mixture
comprises at least two members selected from F4H5, F4H6, F4H8, F6H4, F6H6,
F6H8,
and F6H10, and in particular at least two members selected from F4H5, F6H6,
F4H8,
CA 2834862 2018-09-07
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
9
and F6H8. Furthermore, mixtures of a semifluorinated alkane, e.g. F4H5, with a
perfluorinated compound, such as perfluorooctylbromide or perfluorodecalin, or
with
another oily material are also contemplated. Other oily materials would, for
example,
include silicone oils, triglycerides (e.g. native or synthetic medium-chain
triglycerides), or compounds such as isopropyl myristate. In some preferred
embodiments, however, perfluorinated compounds are absent.
Liquid SFA's are chemically and physiologically inert, colourless and stable.
Their typical densities range from 1.1 to 1.7 g/cm3, and their surface tension
may be
as low as 19 mN/m. SFA's of the RFRH type are insoluble in water but also
somewhat
amphiphilic, with increasing lipophilicity correlating with an increasing size
of the
non-fluorinated segment. Again, for practising the current invention, an SFA
having a
density of at least 1.2 g/cm3 should be selected.
Liquid SFA's of the RFRH type are being used commercially for unfolding and
reapplying a retina, for long-term tamponade as vitreous humor substitute (H.
Meinert et al., European Journal of Ophthalmology, Vol. 10(3), pp. 189-197,
2000),
and as wash-out solutions for residual silicon oil after vitreo-retinal
surgery.
Experimentally, they have also been used as blood substitutes (H. Meinert et
al.,
Biomaterials, Artificial Cells, and Immobilization Biotechnology, Vol. 21(5),
pp. 583-
95, 1993). These applications have established SFA's as physiologically well
tolerated
compounds. On the other hand, SFA's have not been used as excipients in
approved
drug products as of today.
For allowing convenient administration to the nails, the composition is
preferably liquid or semi-solid. As used herein, semi-solid means that a
material
behaves like a solid upon the exertion of low shear force, but above a certain
force
threshold, the so-called "yield point", it behaves like a viscous fluid.
Whether liquid or semi-solid, the composition may represent a single phase
(i.e.
a solution), or consist of two or more phases. A solution may be applied as
such,
preferably using a brush-like applicator, or it may be sprayed on if the
dispenser is
adapted to emit the formulation as an aerosol or spray. Optionally, the
formulation
may contain a film-forming excipient such as a modified cellulose (e.g.
nitrocellulose),
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
an acrylic or methacrylic polymer or copolymer, a polyester,
poly(butylhydrogen
maleate-co-methoxyethylene) or another suitable resin, such as to represent a
nail
lacquer which is applied as a solution and then dries to form a solid film on
the nail. In
addition to a film-forming resin, such composition may contain an excipient
for
5 improving the adhesion of the film-forming material on the nail, such as
a tosylamide-
formaldehyde resin. Moreover, it may contain a plasticiser such as triacetin,
camphor,
a phthalate, triethyl citrate or the like to improve the flexibility of the
film and
decrease its brittleness. It may also be advantages to incorporate a volatile
cosolvent
such as ethyl acetate, ethanol, 1-propanol, 2-propanol, or acetone.
10 In a further embodiment, the composition is in the form of an emulsion.
As used
herein, an emulsion is a system comprising a dispersed (or inner, or
emulsified, or
discontinuous) liquid phase within a continuous (or outer, or coherent) liquid
or
semisolid phase. The two phases are not miscible. In an 0/W-emulsion (also
referred
to as oil-in-water emulsion), a water-immiscible organic liquid phase, which
does not
have to be an "oil" by any specific definition, is dispersed in a water-
miscible
continuous phase which may or may not be substantially comprised of water
itself.
In another embodiment, the composition is in the form of a microemulsion. A
microemulsion is a clear, thermodynamically stable, optically isotropic
mixture of a
lipophilic component, a hydrophilic component, and an amphiphilic component.
Typically, a microemulsion forms spontaneously when the components are
combined
and mixed with each other, without requiring high energy input as is normally
required for the formation of an "ordinary" emulsion. Microemulsions may have
a
colloidal lipophilic phase dispersed in a hydrophilic phase, or a hydrophilic
phase
colloidally dispersed in a lipophilic phase. The size of the dispersed phases
is usually
in the range from about 5 nm to about 400 nm, and most often below about 200
nm.
In one of the preferred embodiments of the invention, the particle size is
from about 5
nm to about 100 nm. In terms of its rheological properties, the microemulsion
may be
in the form of a liquid or a gel, i.e. in liquid or semisolid form. In a
preferred
embodiment, the microemulsion is in liquid form.
For microemulsions according to the invention, it is preferred to use an oil
phase comprising from about 5 to about 95 wt.-% of SFA, and more preferably
from
CA 02834862 2013-10-31
WO 2012/160180
PCT/EP2012/059788
11
about 10 to about 80 wt.-% of SFA, the remainder of the oil phase being
another oil
such as isopropylmyristate. With respect to the incorporation of aqueous
components, surfactants and optionally cosurfactants, commonly known
constituents
of microemulsions may be used to formulate the composition.
It is proposed that emulsions and microemulsions may be particularly suitable
to treat proximal regions of nails at their interface to the skin, in
particular involving
administration to the eponychium, which is the small band of epithelium that
extends
from the posterior nail wall onto the base of the nail. The eponychium is the
end of
the proximal fold that folds back upon itself to shed an epidermal layer of
skin onto
the newly formed nail plate, and therefore it is an important target site for
the
delivery of active ingredients for improving the health of a nail as it is
being formed.
Optionally, the composition may be designed to be administered as a nail
patch.
For this purpose, a liquid or semisolid formulation may be incorporated in a
nonwoven material which is covered and held in place by an adhesive patch.
Alternatively, the active ingredient and the SFA may be incorporated in an
adhesive
matrix layer (drug-in-adhesive design). A further option is to fill a liquid,
SFA-based
drug formulation in a pouch which is covered and applied to the nail by means
of an
adhesive patch (liquid reservoir design). In this case, the pouch has a
(semi)permeable membrane at the interface to the nail, through which the
active
ingredient and the SFA is released to the nail.
The composition, whether formulated as a solution, microemulsion or
conventional emulsion, suspension, or patch, may contain any further
pharmaceutically acceptable ingredients as required or useful in view of the
intended
application. As mentioned above, an additional solvent or co-solvent may be
incorporated, for example in order to achieve a higher solubility for a
specific active
ingredient, to modify the viscosity or stability of the formulation, or to
further
enhance the penetration of the active ingredient. Such co-solvent should of
course be
selected in type, quality and amount such as to maintain the physiological
tolerability
of the formulation. Potentially suitable co-solvents include ethanol, acetone,
ethyl
acetate, isopropyl alcohol, glycerol, propylene glycol, pentylene glycol,
polyethylene
glycol, liquid paraffin, triglyceride oils, hydrofluorocarbons such as HFA
134a and/or
CA 02834862 2013-10-31
WO 2012/160180
PCT/EP2012/059788
12
HFA 227, and liquid mono- or diglycerides. Among these, ethanol, isopropyl
alcohol,
and pentylene glycol are among the particularly preferred solvents. It has
been found
that relatively small amounts of ethanol may substantially modify the
solubilising
properties of SFAs and allow the incorporation of a number of active
ingredients at
higher concentrations. For example, the composition may comprise up to about
25
wt.-%, or up to 10 wt.-% of ethanol, or up to about 5 wt.-% of ethanol. Even
at a low
concentration of up to about 3 wt.-%, ethanol may be a very useful additive in
the
composition, depending on the specific drug substance to be delivered.
Pentylene
glycol is also very useful as co-solvent in general and, in particular, it has
been found
that its incorporation is advantageous in the formulation of microemulsions.
Moreover, the composition may comprise one or more stabilisers, surfactants
(in particular if the composition is in the form of an emulsion or
microemulsion),
cosurfactants (in particular if it is in the form of a microemulsion),
colouring agents,
antioxidants (for example, a-tocopherol), thickeners (viscosity-increasing
agents
such as bentonite), and fragrances.
If a surfactant is present, it may, for example, be selected from
physiologically
acceptable phospholipids (such as phosphatidylcholines); nonionic surfactants
such
as fatty alcohols, pegylated glycerides, pegylated fatty acids, pegylated
fatty alcohols,
pegylated sorbitan fatty acid esters, and poloxamers; anionic surfactants such
as
sodium lauryl sulphate, docusate sodium, and sodium deoxycholate.
The composition may be prepared by commonly known techniques for the
manufacture of pharmaceutical solutions, emulsions, suspensions, gels, sprays,
and
microemulsions. Depending on their consistency and specific use, they may be
presented in bottles, spray bottles, tubes, with or without applicator.
The active ingredient incorporated within the composition may, in principle,
be
selected from drug substances which are useful for the prevention, management,
or
therapy of a disease or condition relating to a nail.
In one of the specific embodiments, the active ingredient is poorly water-
soluble. In particular, it water solubility is not more than about 1 mg/mL. In
other
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
13
preferred embodiments, the water solubility is not higher than about 0.1
mg/mL, or
not more than about 10 1.1g/mL, respectively. The invention is particularly
useful for
delivering such active ingredients because it allows the administration of
effective
doses in relatively small volumes, which is at least partly due to the
surprisingly high
solubilisation capacity of semifluorinated alkanes for many poorly water-
soluble drug
substances.
For the avoidance of doubt, it is affirmed that the invention is not
restricted to
poorly water-soluble drug substances. It has been found that certain bioactive
agents
have substantial aqueous solubility, but can also be advantageously formulated
in
SFA-based carriers.
The active ingredient may be selected from drug substances useful for the
prevention and in particular for the management and therapy of any nail
disease or
condition, or any symptom associated therewith, including nail psoriasis,
onychomycosis, onychia, onychocryptosis, onycholysis, onychomadesis,
onychoptosis, paronychia, onychomatricoma, anonychia, leukonychia,
hapalonychia,
erythronychia, nail dystrophy, nail-patella syndrome, as well as pain,
itching, and
throbbing.
In one of the specific embodiments, the composition is used in the therapy of
nail psoriasis, and incorporates an active ingredient which may be used to
control
psoriasis or a symptom thereof. Such active ingredient may, for example, be an
immunosuppressant drug, such as a macrolide immunosuppressant. Examples of
potentially suitable macrolide immunosuppressants include tacrolimus,
sirolimus,
everolimus, pimecrolimus, ridaforolimus, temsirolimus, zotarolimus, and
ciclosporin
A. Tacrolimus is one of the particularly preferred drugs in this group. It has
been
found by the inventors that tacrolimus can be very effectively (i.e. faster
and deeper
than using conventional formulations) delivered to the nail matrix. The
compound
penetrates the nails at least to a depth of 400 [un (see Example 1).
The composition of the invention may enable penetration of therapeutically
significant doses of generally poor nail-permeating active ingredients, such
as
macrolide immunosuppressant, e.g. tacrolimus, into the nail matrix. For
example, at
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
14
least about 8% of the administered dose of active agent may penetrate the nail
matrix
within 1,000 minutes after topical application of the composition to the nail.
In
another embodiment, at least about 20 M of active ingredient may be found at
a
depth of at least 150 pm, within 1,000 minutes of topical application of the
composition to the nail. In a further embodiment, at least about 10 M of
active
ingredient may be found at a depth of at least 250 m, within 1,000 minutes
after
topical application of the composition to the nail.
Also potentially useful in the treatment of nail psoriasis is the
incorporation of
an active ingredient from the class of retinoids. Examples of such topically
active
retinoids include retinol, retinal, tretinoin, isotretinoin, alitretinoin,
etretinate,
acitretin, tazarotene, bexarotene and adapalene.
Moreover, the incorporation of an active ingredient selected from the class of
vitamin D analogues, in particular vitamin D3 analogues, is a further
treatment option
for nail psoriasis. Examples of these include calcipotriol, calcitriol, and
tacalcitol.
Nail psoriasis, but also other conditions of the nail, may involve substantial
inflammatory reaction which may be addressed by the incorporation of a
corticosteroid or a nonsteroidal anti-inflammatory agent (NSAID). Suitable
corticosteroid which may be incorporated in an SFA-based composition include
amcinonide, betamethasone dipropionate, clobetasol propionate, desonide,
desoximetasone, diflorasone diacetate, fluocinolone acetonide, fluocinonide,
flurandrenolide, fluticasone propionate, halcinonide, halobetasol proprionate,
hydrocortisone, hydrocortisone butyrate, hydrocortisone valerate, mometasone
furoate, prednicarbate, and triamcinolone acetonide. Suitable NSAIDs include
diclofenac, ibuprofen, ketoprofen, indometacin, piroxicam, flufenamic acid,
etofenamate, and flurbiprofen.
Another therapeutic indication in which it is of great importance that the
therapeutic agent penetrates the deeper layers of the affected nail is
onychomycosis,
a fungal infection of the nail. In a particular embodiment, the composition of
the
invention is for use in the treatment of onychomycosis and comprises an
antifungal
agent in a therapeutically effective amount or concentration. Antifungal
agents which
CA 02834862 2013-10-31
WO 2012/160180 PCT/EP2012/059788
may be incorporated for this purpose include compounds selected from azole
antifungals, allylamine antifungals, and others. Proposed for practising the
invention
are in particular clotrimazole, ketoconazole, miconazole, terbinafine,
naftifine,
butenafine, ciclopiroxolamine and amorolfine.
5 The composition of the invention may enable rapid penetration of
therapeutically significant doses of active agent, such as an antifungal agent
(for
example, ciclopiroxolamine). For example, at least about 15% of the
administered
dose of active agent may have penetrated the nail matrix within 1,000 minutes
after
topical application of the composition to the nail. In other embodiments, at
least
10 about 25%, or at least about 40% of the administered dose of active
agent may
penetrate the nail matrix within 1,000 minutes after topical application of
the
composition to the nail.
The composition of the invention may in particular also enable the penetration
of the active agent into the deeper layers of the nail. For example, at least
about 8% of
15 the administered dose of active agent may penetrate to a depth of at
least about 100
p.m, within 1,000 minutes after topical application of the composition to the
nail. In
other embodiments, at least about 3% of the administered dose of active agent
may
penetrate to a depth of at least about 200 p.m, or at least 1% of the
administered dose
of active agent may penetrate to a depth of at least about 400 m, within
1,000
minutes after topical application of the composition to the nail,
In a further embodiment, the composition of the invention comprises a local
anaesthetic agent such as benzocaine, butamben, dibucaine, lidocaine,
oxybuprocaine,
bupivacaine, pramoxine, proparacaine, proxymetacaine, and tetracaine. Such
composition may be used to relieve pain or itching which may be directly or
indirectly caused by various nail diseases and conditions, or which may result
from
their treatment. Moreover, they may be used in preparation of minor surgical
procedures.
Moreover, the composition may comprise an antibiotic agent for use in the
prevention or therapy of a bacterial infection. Examples of suitable locally
active
antibiotics include aminoglycosides such as neomycin or gentamycin; macrolides
CA 02834862 2013-10-31
WO 2012/160180
PCT/EP2012/059788
16
such as erythromycin and azithromycin; tetracyclins such as chlorotetracyclin,
oxytetracyclin, meclocyclin or tetracyclin; and other antibiotics such as
retapamulin,
clindamycin, fusidic acid, mupirocin, clioquinol, nadifloxacin, or
tyrothricin.
The invention is further illustrated by the following examples.
Examples
Example 1
Tacrolimus was dissolved in a liquid carrier comprising F6H8 and 3.8 wt.-%
ethanol to obtain a clear solution having a tacrolimus concentration of 1
mg/mL. The
composition was used to evaluate the penetration of tacrolimus from an SFA-
based
carrier into human nails.
Excised human toe nails were obtained and washed in isotonic sodium chloride
solution. For each nail, a filter membrane of 16 mm in diameter (2.01 cm2) was
loaded with 30 RL of the test solution, placed onto the nail and incubated for
1,000
mm. At the end of the period, the remaining amount of the test solution in the
filter
and on the nail was collected. From each nail, punch biopsies of 5 mm in
diameter
(0.1963 cm2) were obtained. The punch biopsies were frozen and microtomised at
-
40 C into 20 horizontal slices of 40 p.m thickness. Each slice was extracted
and
analysed for tacrolimus by HPLC-MS, as were the collected amounts of non-
permeated formulation.
In result, it was found that tacrolimus was well taken up by the nails during
the
test period. This is surprising in view of the fact that nails are commonly
considered
to be very poorly permeable, and that tacrolimus is, due to its molecular
size, not a
particularly well permeating drug substance. The total amount of tacrolimus
found in
the nails represented approx. 9% of the administered dose. Significant
tacrolimus
concentrations were found as deep as 400 1..im below the nail surface (see
fig. 1). The
respective amounts of the drug in each layer are shown in figure 2.
CA 02834862 2013-10-31
WO 2012/160180
PCT/EP2012/059788
17
Example 2
The experiment of Example 1 was repeated, except that a solution of
ciclopiroxolamine was used instead of a tacrolimus solution. The test
composition
contained 1 % (w/v) of ciclopiroxolamine dissolved in a vehicle of F6F18 and
ethanol
(85/15 wt.-%).
In result, a fraction of 49.5% of the administered amount of ciclopiroxolamine
was found in the nail matrix. Even though the compound has a lower molecular
weight than tacrolimus, this very high amount of penetrated drug is remarkable
and
far beyond expectations. Significant amounts of drug were found throughout the
depth of the nail matrix (see fig. 3), indicating the SFAs are an extremely
promising
vehicle for the delivery of ciclopiroxolamine into nails.
